Objective:To observe the effect of Astragalus preparation on thyrotropin receptor antibody (TRAb) of patients with Graves’ disease. MethodsCollect 173 cases of patients with Graves’ disease from August 2016 to July 2018 and divide them into the control group (117 cases) and the treatment group (56 cases) according to the treatment used. Both groups were treated with methimazole and the treatment group was also given Astragalus preparations (Astragalus capsule, lingqishen oral liquid or TCM decoction containing Astragalus) for 6 months at least. The changes of serum TRAb,free thyroxine (FT,4,) and thyroid stimulating hormone (TSH) were compared between the two groups.  Results:①=3\*GB3The results of ANOVA showed that there was significant statistical significance in the time factor of intragroup variation of TRAb, TSH and FT4 (P,<,0.05); there was significant statistical significance in the time × group factor of TRAb and TSH (P,<,0.05); there was no significant statistical significance in the time × group factor of FT4 (P,>,0.05). There was significant statistical significance in the group factors of TSH (P,<,0.05), but not in TRAb and FT4 (P,>,0.05). ②The differences of serum TRAb, TSH and FT,4, levels in the treatment group were statistically cant beforesignifi and after one-month-treatment (P,<,0.05) and the differences of serum TSH and FT,4, levels in the control group were also significant before and after one-month-treatment (P,<,0.05); The differences of serum TRAb, TSH and FT,4, level in both groups were significant before and after two-month-treatment, three-month-treatment and six-month-treatment respectively (P,<,0.05). ③The differences of serum TRAb level between two groups were statistically significant (P,<,0.05) when compared after 2-month treatment and after 3-month-treatment; there were significant differences (P,<,0.05) in the level of serum TRAb, TSH and FT,4, between two groups after six-month treatment.  Conclusion:With the prolongation of treatment time, compared with the use of methimazole alone, Astragalus preparations can better improve the thyroid function and reduce the serum TRAb level in patients with Graves’ disease.